SCHEMBL2316110

SCHEMBL2316110

CCn1cc(-c2ccncc2)c(-c2cccc(N(CC(=O)OC)S(=O)(=O)c3cc(F)ccc3F)c2C)n1

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARG P37231 16/20 0.35
PPARD Q03181 16/20 0.35
PPARA Q07869 15/20 0.35
MAPK14 Q16539 1/20 0.34
MCOLN3 Q8TDD5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2364647 0.90 PPARG (0.36) PPARGPPARDPPARAMAPK14
SCHEMBL17836539 0.88 MAPK14 (0.34) PPARGPPARDPPARAMAPK14
SCHEMBL2359292 0.87 MAPK14 (0.35) PPARGPPARDPPARAMAPK14
SCHEMBL2317760 0.85 MAPK14 (0.34) PPARGPPARDPPARAMAPK14
SCHEMBL2316585 0.85 BRAF (0.35) MAPK14
SCHEMBL14719040 0.85 CDC7 (0.35) PPARGPPARDPPARAMAPK14
SCHEMBL2359381 0.85 MAPK14 (0.36) PPARGPPARDPPARAMAPK14
SCHEMBL2313322 0.85 MAPK14 (0.35) PPARGPPARDPPARAMAPK14
SCHEMBL14108523 0.85 MAPK14 (0.35) PPARGPPARDPPARAMAPK14
SCHEMBL17836529 0.85 PPARG (0.35) PPARGPPARDPPARAMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP claimed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US claimed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US claimed
EP-2528909-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-12-05 EP claimed
WO-2011092088-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO claimed
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP disclosed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US disclosed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US disclosed
EP-2528909-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-12-05 EP disclosed
WO-2011092088-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K15, MAP3K19, CDK3 PPARG 3770/4885PPARD 2449/4885PPARA 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.